Table 2. Clinical characteristics and outcomes of 8 patients with H275Y mutation of pandemic (H1N1) 2009 virus, Seattle Cancer Care Alliance, Seattle, Washington, USA, May 1, 2009–April 30, 2010*.

Patient no.	Symptoms of URTI	Signs of LRTI	Radiology results	Antiviral drug therapy before resistance	Co-pathogens	Outcome
1	24 h before diagnosis: congestion, headache	Hypoxemia; positive BAL result on d 5	Bilateral ground glass opacity	Oseltamivir 150 mg 2×/d followed by peramivir	None	Death related to influenza
2	48 h before diagnosis: congestion, wet cough, sore throat, fever (24 h)	Hypoxemia; positive BAL result on d 25	Bilateral ground glass opacity	Oseltamivir 150 mg 2×/d + rimantadine 100 mg 2×/d	Pneumocystis spp. (DFA + in BAL)	Alive
3	5 d before diagnosis: fever (24 h), wet cough	Hypoxemia; positive BAL result on d 2	Multiple nodules with halo sign	Oseltamivir 150 mg 2×/d	Aspergillus (PCR and GM result positive in BAL sample); Staphylococcus aureus; PIV3	Alive
4	<24 h before diagnosis: fever (5 d), cough	Hypoxemia	Bilateral infiltrates	Oseltamivir 2 mg/kg 2×/d	None	Alive
5	<24 h before diagnosis: cough, rhinorrhea, congestion	No	Bronchial thickening	Oseltamivir 150 mg 2×/d	None	Alive
6	<24 h before diagnosis: rhinorrhea, fever (24 h), cough	No	None	Oseltamivir 150 mg 2×/d	None	Alive
7	24 h before diagnosis: sore throat, fever (24 h), cough	No	CXR stable	Oseltamivir 75 mg 2×/d + rimantadine 100 mg 2×/d	Rhinovirus (PCR result positive in NW sample)	Alive
8	24 h before diagnosis: sore throat, fever (24 h), chills	No	CXR normal	Prophylaxis: oseltamivir 45 mg 2×/d for 10 d, ended 3 d before influenza diagnosis	None	Alive

*URTI, upper respiratory tract infection; LRTI, lower respiratory tract infection; BAL, bronchoalveolar lavage; DFA, direct immunofluorescence assay; GM, galactomanane; PIV3, parainfluenza virus 3; NW, nasal wash; CXR, chest radiograph.